Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18253226 | 0.70 | — | — | |
| SCHEMBL7934238 | 0.69 | — | — | |
| SCHEMBL18485602 | 0.69 | — | — | |
| SCHEMBL6638059 | 0.67 | — | — | |
| SCHEMBL20995760 | 0.67 | — | — | |
| SCHEMBL4486152 | 0.67 | — | — | |
| SCHEMBL5081893 | 0.64 | — | — | |
| SCHEMBL457485 | 0.64 | — | — | |
| Trifluoroacetic Acid SCHEMBL28132681 | 0.62 | KDM1A (0.35) | — | |
| SCHEMBL18485605 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | claimed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | claimed |
| EP-3548469-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | Nelson Mandela Metropolitan University (ZA) | 2019-10-09 | — | — | EP | claimed |
| WO-2018154414-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2018-08-30 | — | — | WO | claimed |
| CN-110382470-B | Preparation method of efavirenz | 纳尔逊·曼德拉都市大学 | 2023-06-06 | — | — | CN | disclosed |
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | disclosed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | disclosed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | disclosed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | disclosed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | disclosed |
| EP-3548469-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | Nelson Mandela Metropolitan University (ZA) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018154414-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2018-08-30 | — | — | WO | disclosed |
| US-6348616-B1 | CHEMICAL INTERMEDIATES FOR SYNTHESIS OF DESIRED BENZOXAZINONES | PIERCE MICHAEL ERNEST (US) | 2002-02-19 | — | — | US | disclosed |
| US-6303780-B1 | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| US-6147210-A | Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-14 | — | — | US | disclosed |
| US-6140499-A | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICAL COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0929533-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | Du Pont Pharmaceuticals Company (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998014436-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1998004535-A1 | A PRACTICAL SYNTHESIS OF BENZOXAZINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689353-B2 | Method for the manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | FFAR1 2008/4885 |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | FFAR1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.